These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3930064)

  • 1. Buserelin as primary therapy in advanced prostatic carcinoma.
    Presant CA; Soloway MS; Klioze SS; Kosola JW; Yakabow AL; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Ford KS
    Cancer; 1985 Nov; 56(10):2416-9. PubMed ID: 3930064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.
    Presant CA; Soloway MS; Klioze SS; Yakabow A; Presant SN; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Todd B
    Cancer; 1987 May; 59(10):1713-6. PubMed ID: 3103904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buserelin treatment of advanced prostatic cancer: a phase II study.
    Veronesi A; Lo Re G; Dal Bo V; Magri MD; Della Valentina M; Talamini R; Merlo A; Francini M; Monfardini S
    Med Oncol Tumor Pharmacother; 1989; 6(4):255-7. PubMed ID: 2515400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buserelin in the treatment of prostatic cancer.
    Roila F
    Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI; Falkson G; Falkson HC
    Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.
    Klioze SS; Miller MF; Spiro TP
    Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
    Fernandez del Moral P; Litjens TT; Weil EH; Debruyne FM
    Urology; 1988 Aug; 32(2):137-40. PubMed ID: 2969641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS
    Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma.
    Koutsilieris M; Tolis G
    Prostate; 1983; 4(6):569-77. PubMed ID: 6415629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
    Van Cangh PJ; Opsomer RJ
    J Urol; 1987 Jan; 137(1):61-4. PubMed ID: 2948026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
    Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
    Doberauer C; Niederle N; Schmidt CG
    Cancer; 1988 Aug; 62(3):474-8. PubMed ID: 3134119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment in M1 prostate cancer.
    Ferrari P; Castagnetti G; Ferrari G; Pollastri CA; Tavoni F; Dotti A
    Cancer; 1993 Dec; 72(12 Suppl):3880-5. PubMed ID: 8252509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine factors in the treatment of prostatic cancer.
    Pierrepoint CG; Turkes AO; Walker KJ; Harper ME; Wilson DW; Peeling WB; Griffiths K
    Prog Clin Biol Res; 1985; 185A():51-72. PubMed ID: 3162177
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.